Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review...
Kardoust P. M., Abufaraj M., Fajkovic H., Kimura S., Iwata T., D'Andrea D., Karakiewicz P. I., Shariat Sh.
Urologic Oncology
Vol.37, Issue10, P. 637-646
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.urolonc.2019.06.007
Аннотация:
Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95[%]CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34[%], P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95[%]CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95[%]CI 0.00–0.04) in patients treated w
Ключевые слова:
Prostate cancer; Radiation therapy; Radical prostatectomy; Testosterone deficiency; Testosterone Replacement therapy
antineoplastic hormone agonists and antagonists; testosterone; androgen therapy; biochemical recurrence; brachytherapy; cancer hormone therapy; cancer patient; cancer recurrence; cancer survivor; Cochrane Library; cryotherapy; external beam radiotherapy; high intensity focused ultrasound; human; local therapy; Medline; meta analysis; patient safety; priority journal; prostate cancer; prostatectomy; Review; Scopus; systematic review; Web of Science; aged; male; middle aged; mortality; prostate tumor; survival analysis; Aged; Cancer Survivors; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Analysis; Testosterone
Язык текста: Английский
ISSN: 1873-2496
Kardoust P. M. Parizi M.
Abufaraj M.
Fajkovic H.
Kimura S.
Iwata T.
D'Andrea D.
Karakiewicz P. I.
Shariat Sh. Sharokh 1973-
Кардоуст П. М. Паризи М.
Абуфарай М.
Файковиc Х.
Кимура С.
Иwата Т.
Д'Андреа Д.
Каракиеwиcз П. И.
Шариат Ш. Шарох 1973-
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis
Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review...
Текст визуальный непосредственный
Urologic Oncology
Elsevier Science Publisher B.V.
Vol.37, Issue10 P. 637-646
2019
Обзор
Prostate cancer Radiation therapy Radical prostatectomy Testosterone deficiency Testosterone Replacement therapy
antineoplastic hormone agonists and antagonists testosterone androgen therapy biochemical recurrence brachytherapy cancer hormone therapy cancer patient cancer recurrence cancer survivor Cochrane Library cryotherapy external beam radiotherapy high intensity focused ultrasound human local therapy Medline meta analysis patient safety priority journal prostate cancer prostatectomy Review Scopus systematic review Web of Science aged male middle aged mortality prostate tumor survival analysis Aged Cancer Survivors Humans Male Middle Aged Prostatic Neoplasms Survival Analysis Testosterone
Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR). Materials and methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Results: Twenty-one studies were eligible. The overall pooled BCR rate was 0.01 (95[%]CI 0.00–0.02) suggesting a lack of association between TRT and BCR; there was no heterogeneity among included studies (I2 = 24.34[%], P = 0.15). In subgroup analyses, pooled BCR rates were 0.00 (95[%]CI 0.00–0.02) in patients treated with radical prostatectomy and 0.02 (95[%]CI 0.00–0.04) in patients treated w